Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Children's Flonase Is Latest Play For Nasal Allergy Spray Market Share

This article was originally published in The Tan Sheet

Executive Summary

Children's Flonase, like Children's Nasacort, is the same formulation and is indicated for the same overall age groups as the original product, but its labeling includes additional detail for use by children.

You may also be interested in...



Industry Roundup: Children's Rhinocort, MusclePharm Restructuring

Senators stir bulk caffeine criticism; AHPA updates membership process; Weiss heads Nutrition 21; and more news in brief.

First-In-Class Nasacort OTC Also Originates ‘Children’s’ Label

Sanofi introduces Children’s Nasacort Allergy 24HR in the same formulation and dosage as the original OTC switch, but with “children’s” added to the package after approval by FDA. The firm promotes the product as the “first and only” 24-hour multi-symptom nasal allergy spray available OTC for children ages 2 and up.

Nasacort, Flonase Competition Heats Up As Sanofi Appeals NAD Review

Chattem appeals a National Advertising Division decision from a review of advertising comparing its Nasacort nasal allergy spray to GSK’s Flonase. The Sanofi business maintains NAD relied on a “cookbook” approach to determine whether claims for the product are substantiated.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS108242

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel